Nautilus Biotechnology, Inc. reported a 13% decrease in operating expenses for the first quarter of 2025, reflecting continued strategic cost reductions.
The company maintained its robust cash runway through 2027, ensuring ample liquidity for ongoing development and future commercialization efforts.
Significant development progress was made on the Tau proteoform assay, with internal verification and validation work demonstrating its reproducibility, accuracy, and dynamic range. This assay has shown a median Coefficient of Variation (CV) of just 1.5% within-experiment and an exceptional within-analyte dynamic range exceeding four orders of magnitude, capable of reliably quantifying tau forms present at levels as low as 0.1% of total tau.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.